Angiochem is a clinical-stage biotechnology company discovering and developing novel drugs that are crossing the blood-brain barrier to treat brain diseases. These new Engineered Peptide Compounds (EPiC) have the potential to address significant medical needs, many of which cannot be effectively addressed due to the fundamental physiological challenge the blood-brain barrier presents for therapeutic intervention. Angiochem is developing a deep and broad product pipeline, including small and large molecules, for the treatment of a wide range of brain diseases including brain cancers, lysosomal storage disorders, pain and others. The EPiC platform has been strongly validated in humans.
Looking for a particular Angiochem employee's phone or email?
Angiochem Questions
The Angiochem annual revenue was $5.6 million in 2026.
John Huss is the CEO of Angiochem.
3 people are employed at Angiochem.
Angiochem is based in Westmount, Quebec.
The NAICS codes for Angiochem are [541, 54, 32541, 325, 3254, 32].
The SIC codes for Angiochem are [283, 28, 873, 87].
Top Angiochem Employees
-
John Huss
Chief Executive Officer at Angiochem
Bagnes, VS, CH -
Wendy Churchill
Lead Clinical Research Associate at Angiochem
Montreal, QC, CA11
